Unknown

Dataset Information

0

Evaluation of the prognostic significances of ?-secretase genes in pancreatic cancer.


ABSTRACT: With the growing requirement for novel prognostic biomarkers for pancreatic cancer, many studies have focused on clinical and/or genomic variables. Although many studies have been performed, carbohydrate antigen 19-9 is the only biomarker in clinical use. Therefore, the present study examined whether ?-secretase genes, including presenilin (PSEN), nicastrin (NCSTN), presenilin enhancer protein 2 (PSENEN), and anterior pharynx-defective 1 (APH1-), could serve as prognostic factors for pancreatic cancer. The cohorts selected included >100 pancreatic cancer patients. Patient data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GSE21501). The prognostic roles of the ?-secretase genes were analyzed by several survival analysis methods. Among the ?-secretase genes, the prognosis tended to be worse in the 2 cohorts with increasing expression of PSEN1, APH1A, and PSENEN, while the remaining genes were the opposite in the 2 cohorts. Notably, although the patient characteristics were quite different, APH1A was statistically significantly associated with prognosis in the 2 cohorts. The hazard ratio of APH1A for overall survival was 1.598 (TCGA) and 2.724 (GSE21501). These results contribute to the study of ?-secretase in pancreatic cancer. We believe that ?-secretase, particularly APH1A, will be a new prognostic biomarker for pancreatic cancer.

SUBMITTER: Jeon YH 

PROVIDER: S-EPMC6444455 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of the prognostic significances of γ-secretase genes in pancreatic cancer.

Jeon Yun Ho YH   Ha Mihyang M   Kim Sung Won SW   Kim Mun Ju MJ   Lee Chi-Seung CS   Oh Chang-Kyu CK   Han Myoung-Eun ME   Oh Sae-Ock SO   Kim Yun Hak YH  

Oncology letters 20190305 5


With the growing requirement for novel prognostic biomarkers for pancreatic cancer, many studies have focused on clinical and/or genomic variables. Although many studies have been performed, carbohydrate antigen 19-9 is the only biomarker in clinical use. Therefore, the present study examined whether γ-secretase genes, including presenilin (<i>PSEN</i>), nicastrin (<i>NCSTN</i>), presenilin enhancer protein 2 (<i>PSENEN</i>), and anterior pharynx-defective 1 (<i>APH1</i>-), could serve as progno  ...[more]

Similar Datasets

| S-EPMC11310876 | biostudies-literature
| S-EPMC3438318 | biostudies-literature
| S-ECPF-GEOD-37645 | biostudies-other
2012-05-03 | GSE37645 | GEO
2012-05-02 | E-GEOD-37645 | biostudies-arrayexpress
| S-EPMC10331760 | biostudies-literature
| S-EPMC9809326 | biostudies-literature
| S-EPMC4115564 | biostudies-literature
| S-EPMC10505756 | biostudies-literature
| S-EPMC8817114 | biostudies-literature